Collaboration Agreements in the Health Care Equipment & Supplies Industry
111 Contracts & Agreements
- ADNEXUS THERAPEUTICS, INC. (1 contract)
- Affinia Therapeutics Inc. (3)
- Alphatec Holdings, Inc. (2)
- Apollo Endosurgery, Inc. (1)
- Arcturus Therapeutics Ltd. (1)
- Audentes Therapeutics, Inc. (5)
- Bicara Therapeutics Inc. (0)
- Cardiovascular Systems Inc (1)
- Cascadian Therapeutics, Inc. (13)
- CHF Solutions, Inc. (2)
- CORNERSTONE THERAPEUTICS INC (2)
- CV THERAPEUTICS INC (2)
- Dare Bioscience, Inc. (1)
- DarioHealth Corp. (2)
- DEXCOM INC (5)
- Dimension Therapeutics, Inc. (4)
- Felicitex Therapeutics Inc. (3)
- FEMASYS INC (1)
- GenMark Diagnostics, Inc. (2)
- GUIDED THERAPEUTICS INC (3)
- HYPERION THERAPEUTICS INC (1)
- INTENSITY THERAPEUTICS, INC. (4)
- iRhythm Technologies, Inc. (3)
- Juno Therapeutics, Inc. (3)
- Kyverna Therapeutics, Inc. (1)
- Lantheus Holdings, Inc. (3)
- Lexeo Therapeutics, Inc. (1)
- METABASIS THERAPEUTICS INC (3)
- MRI INTERVENTIONS, INC. (2)
- Nemaura Medical Inc. (1)
- Neumora Therapeutics, Inc. (1)
- NovoCure Ltd (3)
- Orexigen Therapeutics, Inc. (3)
- Orthofix Medical Inc. (7)
- Pandion Therapeutics Holdco LLC (2)
- ReWalk Robotics Ltd. (6)
- Senseonics Holdings, Inc. (4)
- Structure Therapeutics Inc. (2)
- Surmodics, Inc. (1)
- Tivic Health Systems, Inc. (1)
- Trius Therapeutics Inc (1)
- Zosano Pharma Corp (4)
- Third Amendment to Collaboration and Commercialization Agreement, by and between the Subsidiary and Ascensia Diabetes Care (Senseonics Holdings, Inc., Filed With SEC on August 8, 2024)
- Collaboration Agreement, dated May 6, 2024, between the Registrant and The Swiss Group for Cancer Research SAKK (INTENSITY THERAPEUTICS, INC., Filed With SEC on August 8, 2024)
- First Amendment to Supply and Collaboration Agreement dated as of May 31, 2024 by and between the Company and DaVita Inc (CHF Solutions, Inc., Filed With SEC on June 6, 2024)
- Collaboration and Research Support Agreement, dated May 17, 2024, by and between Tivic Health Systems, Inc. and The Feinstein Institutes for Medical Research (Tivic Health Systems, Inc., Filed With SEC on May 22, 2024)
- First Amendment to License and Collaboration Agreement (PNT-2002), dated as of January 31, 2024, by and between POINT Biopharma, Inc. and Lantheus Two, LLC and Lantheus Medical... (Lantheus Holdings, Inc., Filed With SEC on May 2, 2024)
- Amended and Restated Collaboration and License Agreement, dated November 20, 2018, by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC) (DEXCOM INC, Filed With SEC on February 8, 2024)
- License and Collaboration Agreement, dated December 29, 2021, between Kyverna Therapeutics, Inc. and Intellia Therapeutics, Inc (Kyverna Therapeutics, Inc., Filed With SEC on January 16, 2024)
- Form of Collaboration Agreement (FEMASYS INC, Filed With SEC on November 15, 2023)
- Collaboration Agreement, dated November 7, 2023, by and between Schrdinger, Inc. and Aconcagua Bio, Inc (Structure Therapeutics Inc., Filed With SEC on November 14, 2023)
- Research Collaboration Agreement, dated February 3, 2021, by and between Cornell University and LEXEO Therapeutics, Inc. as amended by Amendment No. 1, dated February 1, 2022 (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- Research Collaboration and License Agreement, dated September 10, 2021, by and between the Registrant and Amgen Inc (Neumora Therapeutics, Inc., Filed With SEC on August 25, 2023)
- Amended and Restated Exclusive Preferred Partner, Co-Promotion, Development Collaboration and License Agreement by and between Sanofi US Services, Inc. and DarioHealth Corp.,... (DarioHealth Corp., Filed With SEC on August 10, 2023)
- Supply and Collaboration Agreement dated as of June 19, 2023 by and between the Company and DaVita Inc (CHF Solutions, Inc., Filed With SEC on June 21, 2023)
- Collaboration Agreement, by and between Lhotse Bio, Inc. and Schrdinger, LLC, dated October 9, 2020 (Structure Therapeutics Inc., Filed With SEC on January 12, 2023)
- License and Collaboration Agreement between Point Biopharma , Inc. and Lantheus Three, LLC, dated as of November 11, 2022 (Lantheus Holdings, Inc., Filed With SEC on November 14, 2022)
- License and Collaboration Agreement between Point Biopharma, Inc. and Lantheus Two, LLC, dated as of November 11, 2022 (Lantheus Holdings, Inc., Filed With SEC on November 14, 2022)
- Amendment No. 2 to License and Collaboration Agreement between Felicitex Therapeutics Inc. and Eurobio Scientific SA (formerly Diaxonhit), dated February 14, 2022 (Felicitex Therapeutics Inc., Filed With SEC on August 10, 2022)
- Amendment No. 1 to License and Collaboration Agreement between Felicitex Therapeutics Inc. and Diaxonhit, dated July 21, 2014 (Felicitex Therapeutics Inc., Filed With SEC on August 10, 2022)
- License and Collaboration Agreement between Felicitex Therapeutics Inc. and Diaxonhit, dated April 16, 2014 (Felicitex Therapeutics Inc., Filed With SEC on August 10, 2022)
- Second Amendment to Collaboration and Commercialization Agreement, by and between the Subsidiary and Ascensia Diabetes Care Holdings AG, dated as of June 21, 2022 (Senseonics Holdings, Inc., Filed With SEC on August 9, 2022)
- Clinical Trial Collaboration and Supply Agreement dated May 18 (NovoCure Ltd, Filed With SEC on May 26, 2022)
- Exclusive Preferred Partner, Co-Promotion, Development Collaboration and License Agreement by and between Sanofi US Services, Inc. and DarioHealth Corp., dated February 28, 2022 (DarioHealth Corp., Filed With SEC on May 12, 2022)
- Second amendment to development collaboration agreement by and among Verily Life Sciences LLC, Verily Ireland Limited, and iRhythm Technologies, Inc (iRhythm Technologies, Inc., Filed With SEC on February 28, 2022)
- First amendment to development collaboration agreement by and among Verily Life Sciences LLC, Verily Ireland Limited, and iRhythm Technologies, Inc (iRhythm Technologies, Inc., Filed With SEC on February 28, 2022)
- Amended and Restated Matrix Commercialization Collaboration Agreement, entered into as of February 7, 2022, by and between Orthofix US LLC and Muscoloskeletal Transplant... (Orthofix Medical Inc., Filed With SEC on February 25, 2022)
- Sponsored Research Collaboration Agreement by and between the Registrant and The Institute of Molecular and Clinical Ophthalmology Basel, dated as of June 22, 2021 (Affinia Therapeutics Inc., Filed With SEC on January 4, 2022)
- Collaboration Agreement by and among the Registrant and Rheinische Friedrich-Wilhelms-Universitt Bonn and Universittsklinikum Bonn, dated as of June 11, 2021 (Affinia Therapeutics Inc., Filed With SEC on January 4, 2022)
- Strategic Collaboration and License Agreement by and between the Registrant and Vertex Pharmaceuticals Incorporated., dated as of April 14, 2020 (Affinia Therapeutics Inc., Filed With SEC on January 4, 2022)
- Material Transfer and Collaboration Agreement, dated March 18, 2021, between the Registrant and Ontario Institute for Cancer Research, Ottawa Hospital Research Institute and Dr.... (INTENSITY THERAPEUTICS, INC., Filed With SEC on November 12, 2021)
- Clinical Trial Collaboration and Supply Agreement, dated June 21, 2019, between the Registrant and MSD International GmbH (INTENSITY THERAPEUTICS, INC., Filed With SEC on October 28, 2021)
- Clinical Trial Collaboration and Supply Agreement, dated April 13, 2020, between the Registrant and Bristol-Myers Squibb Company (INTENSITY THERAPEUTICS, INC., Filed With SEC on October 28, 2021)
- Amendment No. 4 to Research Collaboration Agreement, dated October 14, 2021, between ReWalk Robotics Ltd. and the President and Fellows of Harvard College (ReWalk Robotics Ltd., Filed With SEC on October 18, 2021)
- First Amendment to Collaboration and Commercialization Agreement (Senseonics Holdings, Inc., Filed With SEC on August 9, 2021)
- First Addendum dated June 9, 2020 to License and Collaboration Agreement, dated as of September 10, 2018, between NovoCure Limited and Zai Lab (Shanghai) Co., Ltd (NovoCure Ltd, Filed With SEC on February 25, 2021)
- Research Collaboration Agreement, dated May 16, 2016, between the Company and the President and Fellows of Harvard College (ReWalk Robotics Ltd., Filed With SEC on February 18, 2021)
- Collaboration and Commercialization Agreement, by and between Senseonics, Incorporated and Ascensia Diabetes Care Holdings AG, dated as of August 9, 2020 (Senseonics Holdings, Inc., Filed With SEC on November 9, 2020)
- License and Collaboration Agreement, dated October 30, 2019, by and between the Registrant and Astellas Pharma Inc (Pandion Therapeutics Holdco LLC, Filed With SEC on July 13, 2020)
- Amendment No. 3 to the Research Collaboration Agreement, dated April 30, 2020, between the Company and the President and Fellows of Harvard College (ReWalk Robotics Ltd., Filed With SEC on July 7, 2020)
- License and Collaboration Agreement, dated October 30, 2019, by and between the Registrant and Astellas Pharma Inc (Pandion Therapeutics Holdco LLC, Filed With SEC on June 26, 2020)
- Development collaboration agreement by and among Verily Life Sciences LLC, Verily Ireland Limited, and iRhythm Technologies, Inc (iRhythm Technologies, Inc., Filed With SEC on December 23, 2019)